51 news items
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
VTYX
13 Jun 24
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
AEMD
AIRJ
AONC
6 Jun 24
Bill Kirk maintained United Natural Foods with a Neutral and raised the price target from $13 to $14.
Lululemon Athletica
Oppenheimer Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $10
VTYX
6 Jun 24
Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from $12 to $10.
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
VTYX
6 Jun 24
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
VTYX
5 Jun 24
and immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R
aoxnkj1k6uj1rvt8r7y9wjxmwkjjm2tblptjbn6rw4qh8rkrc7e4f0bhnr
VTYX
3 Jun 24
endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based
y29zur7w02wfido2slpwvepuyr9l9c1lg 9kzw2bw
VTYX
16 May 24
to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader
zw3a 5jn98p
VTYX
30 Apr 24
internal target to support advancement of VTX958 in plaque psoriasis." Based on these results, the Company announced that it "will terminate ongoing
z6qfinr00l7ee17gxof6ffyvip29pbbl5p8jdmx0y0ret5p 5gwlpyeaik
VTYX
29 Apr 24
] internal target to support advancement of VTX958," and that the trial would be terminated.
On this news
fahpc7cismwm96jwl 6oe99udgcdoqvenq73fpj8n0lp8zz7tnkrmlh76li
VTYX
28 Apr 24
observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based on these results, the Company
ltqhmfo9fkglztowklzktguqj9r2xpww1e79g1mhamucat8p
VTYX
25 Apr 24
achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque
89mz04 onbi4wp8lccz4lat4x
VTYX
25 Apr 24
[the Company's] internal target to support advancement of VTX958," and that the trial would be terminated. On this news, Ventyx's stock price
7kex07xjnsagmse1swuwcdy4skqxjb16xdujpx
VTYX
24 Apr 24
[the Company's] internal target to support advancement of VTX958," and that the trial would be terminated. On this news, Ventyx's stock price fell $11.36
chz150jr3h9ijb4levezx ucxe
VTYX
24 Apr 24
endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based
smsy8c82 szulfoy7tkpna0wpdlo
VTYX
23 Apr 24
internal target to support advancement of VTX958 in plaque psoriasis." Based on these results, the Company announced that it "will terminate ongoing
017n 640336i
VTYX
22 Apr 24
the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958
v5jgafr
AVXL
CKPT
VTYX
20 Apr 24
, the Company disclosed that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target
nz6n3tj3fja97cc49 2l
VTYX
20 Apr 24
of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based on these results
makso4s1qdtg5v6ozcsi8nkuyo7eylcz4htvink7lrl8
VTYX
17 Apr 24
of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis." Therefore, the Company "will terminate ongoing
sux s41ch7kcdcflc7uwehh0rlzmy7vw
VTYX
17 Apr 24
that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement